Valsartan Intensified Primary Care Reduction of Blood Pressure Study (VIPER-BP)
Hypertension

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, valsartan
Eligibility Criteria
Inclusion Criteria:
- newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner
Exclusion Criteria:
- significantly elevated blood pressure (severe hypertension)
- requiring 3 or more antihypertensive drugs
- severe kidney disease or dialyses
- clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- Novartis Pharmaceuticals
- Professor Garry Jennings-Co Principal Investigator
- Professor Simon Stewart-Principal Investigator
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Usual care
Monotherapy (initial monotherapy arm)
Combination (initial combination therapy arm)
Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.